Haemostasis is the physiological process that stops bleeding at the site of vascular injury. It involves three main steps: vasoconstriction, primary platelet plug formation, and the coagulation cascade which solidifies the plug into a stable fibrin mesh. Antihaemorrhagic agents, also known as haemostatic agents, are pharmacological substances used to promote clotting and prevent excessive blood loss. These drugs are vital in emergency settings, major surgeries, and bleeding disorders like haemophilia. Without proper haemostatic balance, patients risk severe haemorrhagic shock and death. Nurses must understand this baseline physiology to recognize when and why these drugs are administered.
Antihaemorrhagic agents are grouped based on how they interact with the clotting cascade or physical bleeding sites.
Systemic agents travel via the bloodstream to manage generalized or inaccessible bleeding. Aminocaproic acid and tranexamic acid prevent plasminogen from turning into plasmin, stabilizing clots in hyperfibrinolytic states. Desmopressin (DDAVP) stimulates the release of von Willebrand factor and Factor VIII from endothelial storage sites, making it useful in mild haemophilia A and von Willebrand disease. Blood products such as fresh frozen plasma and cryoprecipitate provide multiple clotting factors simultaneously when specific deficiencies are unknown or multiple factors are depleted.
When bleeding is localized and accessible, topical haemostatic agents provide rapid control during surgical procedures or severe trauma.
Antihaemorrhagic agents are indicated across various clinical scenarios, including postpartum haemorrhage, major trauma, epistaxis, and surgical procedures in patients with bleeding disorders. Nurses must verify the exact indication, check baseline laboratory values like partial thromboplastin time and international normalized ratio, and ensure correct administration routes. In emergency obstetric settings, oxytocin combined with tranexamic acid is standard for managing postpartum blood loss. Accurate timing and dose calculation prevent both treatment failure and thrombotic complications.
Using antihaemorrhagic agents requires careful patient evaluation because promoting clotting can be dangerous in certain states. Active thromboembolic conditions, such as deep vein thrombosis or pulmonary embolism, are strict contraindications for systemic antifibrinolytics. Hypersensitivity to bovine or human blood products prohibits the use of specific topical sealants. Nurses must review the patient's medical history for recent myocardial infarction or stroke before administering systemic clotting promoters.
The primary risk associated with antihaemorrhagic therapy is unwanted thrombosis, which can manifest as deep vein thrombosis, pulmonary embolism, or myocardial infarction. Rapid intravenous injection of certain agents like tranexamic acid can cause severe hypotension, dizziness, and visual disturbances. Topical agents may cause local tissue irritation, allergic reactions, or paradoxical foreign body granulomas. Nurses must be vigilant for signs of compromised peripheral circulation or respiratory distress following administration.
Comprehensive nursing care involves continuous monitoring of vital signs, fluid balance, and site-specific bleeding indicators. Nurses must regulate intravenous infusion pumps carefully to prevent rapid administration errors. For patients receiving topical agents, documenting the exact product used and any material left inside a surgical cavity is legally and clinically required. Education regarding signs of thrombosis, such as unilateral calf swelling or chest pain, ensures prompt intervention if complications arise post-discharge.